|
1
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pan J, Jin P, Yan J and Kabelitz D:
Anti-angiogenic active immunotherapy: a new approach to cancer
treatment. Cancer Immunol Immunother. 57:1105–1114. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chung AS and Ferrara N: Developmental and
pathological angiogenesis. Annu Rev Cell Dev Biol. 27:563–584.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Potente M, Gerhardt H and Carmeliet P:
Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang X, Zhang XF, Lu X, Jia HL, Liang L,
Dong QZ, Ye QH and Qin LX: MicroRNA-26a suppresses angiogenesis in
human hepatocellular carcinoma by targeting hepatocyte growth
factor-cMet pathway. Hepatology. 59:1874–1885. 2014. View Article : Google Scholar
|
|
6
|
Shojaei F: Anti-angiogenesis therapy in
cancer: Current challenges and future perspectives. Cancer Lett.
320:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Croci DO, Cerliani JP, Dalotto-Moreno T,
et al: Glycosylation-dependent lectin-receptor interactions
preserve angiogenesis in anti-VEGF refractory tumors. Cell.
156:744–758. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Astorgues-Xerri L, Riveiro ME,
Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E and
Faivre S: Unraveling galectin-1 as a novel therapeutic target for
cancer. Cancer Treat Rev. 40:307–319. 2014. View Article : Google Scholar
|
|
9
|
Cross MJ and Claesson-Welsh L: FGF and
VEGF function in angiogenesis: signalling pathways, biological
responses and therapeutic inhibition. Trends Pharmacol Sci.
22:201–207. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miller K, Wang M, Gralow J, Dickler M,
Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE:
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic
breast cancer. N Engl J Med. 357:2666–2676. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren S, Fengyu, Zuo S, Zhao M, Wang X, Wang
X, Chen Y, Wu Z and Ren Z: Inhibition of tumor angiogenesis in lung
cancer by T4 phage surface displaying mVEGFR2 vaccine. Vaccine.
29:5802–5811. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bracarda S, Caserta C, Sordini L, Rossi M,
Hamzay A and Crinò L: Protein kinase inhibitors in the treatment of
renal cell carcinoma: Sorafenib. Ann Oncol. 18(Suppl 6): vi22–vi25.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei YQ, Wang QR, Zhao X, et al:
Immunotherapy of tumors with xenogeneic endothelial cells as a
vaccine. Nat Med. 6:1160–1166. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seavey MM, Maciag PC, Al-Rawi N, Sewell D
and Paterson Y: An anti-vascular endothelial growth factor receptor
2/fetal liver kinase-1 Listeria monocytogenes anti-angiogenesis
cancer vaccine for the treatment of primary and metastatic
Her-2/neu+ breast tumors in a mouse model. J Immunol.
182:5537–5546. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zuo SG, Chen Y, Wu ZP, et al: Orally
administered DNA vaccine delivery by attenuated Salmonella
typhimurium targeting fetal liver kinase 1 inhibits murine Lewis
lung carcinoma growth and metastasis. Biol Pharm Bull. 33:174–182.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Y, Wang MN, Li H, King KD, Bassi R, Sun
H, Santiago A, Hooper AT, Bohlen P and Hicklin DJ: Active
immunization against the vascular endothelial growth factor
receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp
Med. 195:1575–1584. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nair S, Boczkowski D, Moeller B, Dewhirst
M, Vieweg J and Gilboa E: Synergy between tumor immunotherapy and
antiangiogenic therapy. Blood. 102:964–971. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pan J, Heiser A, Marget M, Steinmann J and
Kabelitz D: Enhanced antimetastatic effect of fetal liver kinase 1
extracellular domain and interferon-gamma fusion gene-modified
dendritic cell vaccination. Gene Ther. 12:742–750. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong Y, Qian J, Ibrahim R, Berzofsky JA
and Khleif SN: Identification of H-2Db-specific CD8+ T-cell
epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor
growth. J Immunother. 29:32–40. 2006. View Article : Google Scholar
|
|
22
|
Hansen T, Yu YY and Fremont DH:
Preparation of stable single-chain trimers engineered with peptide,
beta2 microglobulin, and MHC heavy chain. Curr Protoc Immunol
Chapter. 17:Unit 17. 152009.
|
|
23
|
Huang CH, Peng S, He L, Tsai YC, Boyd DA,
Hansen TH, Wu TC and Hung CF: Cancer immunotherapy using a DNA
vaccine encoding a single-chain trimer of MHC class I linked to an
HPV-16 E6 immunodominant CTL epitope. Gene Ther. 12:1180–1186.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kang TH, Mao CP, La V, Chen A, Hung CF and
Wu TC: Innovative DNA vaccine to break immune tolerance against
tumor self-antigen. Hum Gene Ther. 24:181–188. 2013. View Article : Google Scholar :
|
|
25
|
Hung CF, Calizo R, Tsai YC, He L and Wu
TC: A DNA vaccine encoding a single-chain trimer of HLA-A2 linked
to human mesothelin peptide generates anti-tumor effects against
human mesothelin-expressing tumors. Vaccine. 25:127–135. 2007.
View Article : Google Scholar
|
|
26
|
Huang B, Mao CP, Peng S, He L, Hung CF and
Wu TC: Intradermal administration of DNA vaccines combining a
strategy to bypass antigen processing with a strategy to prolong
dendritic cell survival enhances DNA vaccine potency. Vaccine.
25:7824–7831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim S, Zuiani A, Carrero JA and Hansen TH:
Single chain MHC I trimer-based DNA vaccines for protection against
Listeria monocytogenes infection. Vaccine. 30:2178–2186. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim S, Li L, McMurtrey CP, Hildebrand WH,
Weidanz JA, Gillanders WE, Diamond MS and Hansen TH: Single-chain
HLA-A2 MHC trimers that incorporate an immundominant peptide elicit
protective T cell immunity against lethal West Nile virus
infection. J Immunol. 184:4423–4430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheung YK, Cheng SC, Ke Y and Xie Y: Two
novel HLA-A*0201 T-cell epitopes in avian H5N1 viral nucleoprotein
induced specific immune responses in HHD mice. Vet Res. 41:242010.
View Article : Google Scholar
|
|
30
|
Cheung YK, Cheng SC, Sin FW, Chan KT and
Xie Y: Investigation of immunogenic T-cell epitopes in SARS virus
nucleocapsid protein and their role in the prevention and treatment
of SARS infection. Hong Kong Med J. 14(Suppl 4): 27–30.
2008.PubMed/NCBI
|
|
31
|
Cheung YK, Cheng SC, Sin FW, Chan KT and
Xie Y: Induction of T-cell response by a DNA vaccine encoding a
novel HLA-A*0201 severe acute respiratory syndrome coronavirus
epitope. Vaccine. 25:6070–6077. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu YX, Li M, Jia XH, Du QX, Miao FT, Yao L
and Shen JD: HPV16 CTL epitope peptide-activated dendritic cell and
natural killer co-culture for therapy of cervical cancer in an
animal model. Asian Pac J Cancer Prev. 14:7335–7338. 2013.
View Article : Google Scholar
|
|
33
|
Wang D, Stockard CR, Harkins L, et al:
Immunohistochemistry in the evaluation of neovascularization in
tumor xenografts. Biotech Histochem. 83:179–189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ellis LM and Hicklin DJ: VEGF-targeted
therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer.
8:579–591. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ebos JM, Lee CR and Kerbel RS: Tumor and
host-mediated pathways of resistance and disease progression in
response to antiangiogenic therapy. Clin Cancer Res. 15:5020–5025.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu YY, Netuschil N, Lybarger L, Connolly
JM and Hansen TH: Cutting edge: Single-chain trimers of MHC class I
molecules form stable structures that potently stimulate
antigen-specific T cells and B cells. J Immunol. 168:3145–3149.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lybarger L, Yu YY, Miley MJ, Fremont DH,
Myers N, Primeau T, Truscott SM, Connolly JM and Hansen TH:
Enhanced immune presentation of a single-chain major
histocompatibility complex class I molecule engineered to optimize
linkage of a C-terminally extended peptide. J Biol Chem.
278:27105–27111. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kanagawa N, Yanagawa T, Nakagawa T, Okada
N and Nakagawa S: Tumor vessel-injuring ability improves antitumor
effect of cytotoxic T lymphocytes in adoptive immunotherapy. Cancer
Gene Ther. 20:57–64. 2013. View Article : Google Scholar :
|
